Merck & Co., Inc. (NYSE:MRK) Holdings Cut by Foundry Partners LLC

Foundry Partners LLC trimmed its position in Merck & Co., Inc. (NYSE:MRKFree Report) by 24.9% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 139,390 shares of the company’s stock after selling 46,268 shares during the period. Foundry Partners LLC’s holdings in Merck & Co., Inc. were worth $14,350,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the company. Moneta Group Investment Advisors LLC lifted its position in shares of Merck & Co., Inc. by 103,159.7% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 39,327,490 shares of the company’s stock valued at $4,363,385,000 after acquiring an additional 39,289,404 shares in the last quarter. Norges Bank purchased a new stake in Merck & Co., Inc. in the 4th quarter worth about $2,736,293,000. Bank of Montreal Can purchased a new stake in Merck & Co., Inc. in the 2nd quarter worth about $740,061,000. Renaissance Technologies LLC lifted its stake in Merck & Co., Inc. by 2,671.4% in the 1st quarter. Renaissance Technologies LLC now owns 5,099,334 shares of the company’s stock worth $418,400,000 after acquiring an additional 4,915,334 shares in the last quarter. Finally, Barclays PLC lifted its stake in Merck & Co., Inc. by 184.5% in the 2nd quarter. Barclays PLC now owns 7,254,914 shares of the company’s stock worth $837,144,000 after acquiring an additional 4,705,004 shares in the last quarter. Institutional investors and hedge funds own 74.59% of the company’s stock.

Insider Activity

In other news, EVP Steven Mizell sold 50,694 shares of the business’s stock in a transaction that occurred on Friday, February 2nd. The stock was sold at an average price of $126.65, for a total transaction of $6,420,395.10. Following the sale, the executive vice president now directly owns 23,619 shares in the company, valued at $2,991,346.35. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.20% of the stock is currently owned by company insiders.

Merck & Co., Inc. Stock Performance

MRK stock traded down $0.84 on Monday, reaching $124.61. 1,070,439 shares of the company were exchanged, compared to its average volume of 7,913,307. Merck & Co., Inc. has a 12 month low of $99.14 and a 12 month high of $128.06. The stock’s fifty day moving average price is $114.58 and its 200 day moving average price is $108.49. The firm has a market capitalization of $315.76 billion, a PE ratio of 896.07, a PEG ratio of 1.62 and a beta of 0.38. The company has a debt-to-equity ratio of 0.82, a current ratio of 1.38 and a quick ratio of 1.12.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last posted its quarterly earnings data on Thursday, February 1st. The company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.12. Merck & Co., Inc. had a net margin of 0.61% and a return on equity of 9.07%. The company had revenue of $14.63 billion for the quarter, compared to the consensus estimate of $14.49 billion. During the same quarter in the previous year, the firm posted $1.62 EPS. The business’s revenue was up 5.8% compared to the same quarter last year. On average, research analysts anticipate that Merck & Co., Inc. will post 8.6 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 5th. Stockholders of record on Friday, March 15th will be given a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a dividend yield of 2.47%. The ex-dividend date of this dividend is Thursday, March 14th. Merck & Co., Inc.’s dividend payout ratio is presently 2,200.00%.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. BMO Capital Markets raised shares of Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and set a $132.00 price target for the company in a research report on Friday, October 27th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Merck & Co., Inc. in a research report on Thursday, November 9th. They issued a “buy” rating and a $115.00 target price for the company. Truist Financial increased their price objective on Merck & Co., Inc. from $122.00 to $139.00 and gave the stock a “buy” rating in a report on Friday, February 2nd. UBS Group raised their price target on Merck & Co., Inc. from $135.00 to $148.00 and gave the stock a “buy” rating in a research note on Friday, February 2nd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $135.00 price target on shares of Merck & Co., Inc. in a research note on Monday, February 5th. Five investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $129.68.

Check Out Our Latest Report on Merck & Co., Inc.

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Read More

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.